Asiatic acid influences parasitaemia reduction and ameliorates malaria anaemia in P. berghei infected Sprague–Dawley male rats by G. A. Mavondo et al.
RESEARCH ARTICLE Open Access
Asiatic acid influences parasitaemia
reduction and ameliorates malaria
anaemia in P. berghei infected
Sprague–Dawley male rats
G. A. Mavondo* , B. N. Mkhwananzi, M. V. Mabandla and C. T. Musabayaneˆ
Abstract
Background: Current malaria treatment is either “anti-parasitic”, “anti-infectivity” or both without addressing
the pathophysiological derangement (anti-disease aspect) associated with the disease. Asiatic acid is a natural
phytochemical with oxidant, antioxidant and anti-inflammatory properties whose effect on malarial and
accompanying pathophysiology are yet to be investigated. Asiatic acid influence in P. berghei-infected
Sprague Dawley rats on %parasitaemia and malarial anaemia were investigated.
Methods: Plasmodium berghei-infected rats (90–120 g) were orally administered with Asiatic acid (5, 10, 20 mg/kg)
and 30 mg/kg chloroquine as a positive control. Changes in %parasitaemia and haematological parameters in
Asiatic acid administered rats were monitored in a 21 day study and compared to controls.
Results: All animals developed stable parasitaemia (15-20 %) by day 7. Asiatic acid doses suppressed parasitaemia,
normalised haematological measurements and influenced biophysical characteristics changes. Most positive
changes were associated with intragastric administration of 10 mg/kg Asiatic acid dose. Peak %parasitaemia in
Asiatic acid administration occurred at days 12 with a shorter time course compared to day 9 for chloroquine
(30 mg/kg) treatment with a longer time course.
Conclusions: Oral Asiatic acid administration influenced %parasitaemia suppression, ameliorated malarial anaemia
and increased biophysical properties on infected animals. Asiatic acid may be a replacement alternative for
chloroquine treatment with concomitant amelioration of malaria pathophysiology. Due to different action time
courses, Asiatic acid and chloroquine may be possible candidates in combination therapy.
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Background
One or more of the five Plasmodium species known to
infect human beings cause malaria accounting the death
of over 600, 000 people annually, a majority of which are
pregnant women and children less than 5 years of age [1].
The pathophysiology of malaria, which is the “malaria
disease”, include immunological aberrations, inflamma-
tion, haemolysis with severe malaria anaemia [SMA] [2],
acute renal failure and general cachexia [3] and malaria
cachexia leading to cardiac failure [4]. Pathophysiological
manifestations during or after successful treatment of
infection are major causes of high morbidity and mortality
associated with malaria [5]. Untoward post treatment
effects with artemisinins and chloroquine and drug resis-
tance affect the mono therapeutic usage of these historical
drugs [6]. Novel anti-inflammatory and immunoregulatory
functions of artemisinin and its derivatives has been re-
ported to inhibit nitric oxide (NO) and proinflammatory
cytokines production by suppressing MRPK and NF-kβ
in macrophages cell line RAW 264.7 [7]. However, the
continued need of for antipyretic supportive paracetamol
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(acetaminophen) therapy prolongs parasite clearance time
by decreasing induced tumour necrosis factor-α (TNF-α)
and may worsen the disease with its inadequate “anti-
disease effects” necessitating continuing search for more
effective “anti-parasitic” or “anti-infection” or both.
Efforts to use adjunctive therapy in malaria, born out
of the identification of malaria pathophysiology resolution
was key to treatment of the disease, have not managed
to reduce malaria morbidity and mortality. Dexametha-
sone (steroid), antibodies against TNF-α, phenobarbital
(anti-convulsant) and iron chelation with desferrioxamine
administration in malaria have not yielded expected
outcomes. Therefore, there still exists an acute need for
antimalarial drugs with anti-parasitic, anti-infectivity and
anti-disease properties. Aberrant immune response and
uncontrolled inflammatory process driven by increasing
parasitaemia in malaria, formulate a significant part of a
vicious cycle in a feed-forward mechanism leading to
severe malaria anaemia, general cachexia, coma and death
from the disease [8]. Hypothetically, drugs that may
inhibit or reverse malaria pathophysiology or the disease
components have a higher chance of controlling malaria
even without parasite eradication through targeting growth
essential host related factors such as severe malaria
anaemia [SMA] an independent malaria mortality predictor
in pregnant women and children. We hypothesized that
triterpenes with anti-disease properties in other conditions
similar to malaria, like inflammation in sepsis and hypoxia
in anaemia may be able to eradicate the Plasmodium para-
site as well as resolve the ensuing pathophysiology.
Triterpenes with pleiotropic functions, sufficient to be
anti-disease as well as anti-parasitic have been reported.
Betulinic acid [BA] (IC50 19.6 and 25.9 μg/mL), ursolic
acid [UA] (IC50 36.5 and 28 μg/mL) and oleanolic acid
[OA] (88.8 and 70.6 μg/mL) have been shown to have
moderate activity in vitro against the chloroquine insen-
sitive (K1) and chloroquine sensitive (T9–96) Plasmodium
falciparum parasites [9]. Maslinic acid, a possible multi
targeting antimalarial, effectively inhibited proteolytic
processing of the merozoite surface protein (MSP1) com-
plex, inhibited the metalloproteases and revealed (in silico
studies) two targets while suggesting several putative new
binding sites for the natural triterpene [10]. This multi-
target phenomenon suppresses the parasitaemia and avoids
the age old preoccupation with targeting single process of
the parasite infective cycle (which is mutation prone) to in-
volve host-related responses potentiating anti-disease and
anti-resistance outcomes.
Asiatic acid (AA), an amphiphilic triterpene, with
known antioxidant and pro-oxidant capacity [11], anti-
inflammatory and antinociception activity in mice [12],
calcium-release associated apoptosis induction [13] and a
potent immunomudulator shares structural and bioacti-
vity properties with OA, MA, UA and BA making it a
possible antimalarial agent. Indeed, prophylaxis activity of
AA has recently been suggested [14] together with its
influences on glucose homeostasis in malaria [15].
Proper interventions may inhibit malarial pathology
development which should be the aim of malaria manage-
ment seeing that people living in endemic areas develop
partial to total immunity against the parasite and asymp-
tomatic parasitaemia is common [16]. Therefore, targeting
the pathophysiology of malaria as well as the parasite may
provide a new mechanism of combating malaria. It is
noteworthy that the diseases and conditions AA is known
to attenuate, inhibit or ameliorate formulate the bedrock
of malaria disease and sequalae as alluded earlier [2, 3,
17–19]. However, there is little information on the anti-
malarial, haematological, immunological impact of AA in
malaria, facets that require exploration for possible AA
pharmacotherapeutic uses. Malaria is driven by glycosyl-
phosphatidylinositol (GPI) which elicits excessive macro-
phages activation leading to proinflammatory cytokine
release, tissue damage, erythophagocytosis, erythropoiesis
dysfunction and general cachexia, require an animal
model to unravel the complex disease pathophysiology
[20]. AA modulates immunity by selective induction of
mitochondria-dependent apoptosis of activated lympho-
cytes in the prevention of murine fulminant hepatitis
[21] a mechanism that may be extendable to malaria.
Using membrane DNA array technique, a wound-healing
derivative of AA [2-Oxo-3, 23-isopropylidene-asiatate (AS
2006A)] exerted anti-inflammatory effect through selec-
tive cytotoxicity to activated macrophage cell line (L-929)
by upregulating expression of apoptosis-inducing genes
caspase-8, c-myc, inducible nitric oxide synthase (iNOS),
mdm2, NF-kβα, I-kβα, and NF-kβ p105 [22]. The finding
may allude to AA also exerting anti-inflammatory
effect by cytochrome c release, caspase 3 activation
and poly(ADP-ribose) polymerase cleavage mechanism as
did AS2006A which may require possibly elucidation in
vivo experiments.
The effect of AA in alleviating haemodynamic and
metabolic alterations in rats with metabolic syndrome
through restoration of endothelium nitric oxide synthase
(eNOS)/iNOS expression [23] has been reported. Similar
AA influence in murine malaria may be anticipated
where eNOS/iNOS ratio determines the bioavailability
of NO necessary for proliferation and angiogenesis [24].
Derangements of this relationship may formulate mala-
rial microvascular pathology.
Limitations inherent in in vitro studies and the inaccess-
ibility of the human host further navigates research of this
nature to an animal model with works by Thaane, T on
maslinic acid (MA) [25] and by Mbatha B OA [26] in the
murine malaria animal model suggesting amelioration of
pathophysiological derangements in malaria. Furthermore,
Centella asiatica, from which naturally occurring AA is
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obtained, was used to treat malaria related fevers [27]
although no specific mention of the phytochemical has
been associated with malarial treatment. In vitro studies,
whilst they may show the molecular interaction of AA
with the parasite, they fall short where the pathophy-
siology of the disease are being explored as in this current
study. In recognition of this, AA antimalarial and its
malaria pathophysiology ameliorative effects were inves-
tigated in P. berghei- infected young (90–120 g) male
Sprague Dawley rats as a novel effect of AA in malaria.
Methods
Materials
Drugs, chemical and accessories
AA (97 % purity), chloroquine diphosphate and dimethyl
sulphoxide (DMSO) were purchased from Sigma-Aldrich
(St. Louis, Missouri, USA). All other chemicals and re-
agents used were of analytical grade.
Animals
Male Sprague–Dawley (SD) rats (90–120 g) were obtained
from the Biomedical Research Unit (BRU), of the Univer-
sity of KwaZulu-Natal where they were bred and housed
for the entire experiment period. Animals were housed
communally and individually in Makrolon polycarbonate
metabolic cages (Techniplast, Labotec, South Africa) dur-
ing experiments. The animals were kept under maintained
laboratory conditions of constant temperature (22 ± 1 °C);
C02 (<5000 ppm), humidity of 55 ± 5 % and illumination
(12 h light/dark cycles) with access to standard rat chow
(Meadows Feeds, Pietermaritzburg, South Africa) and
water ad libitum. All animals were sacrificed by day 21
through exposure to lethal anaesthetic inhalation of isofor
(Safeline Pharmaceuticals, Rooderport, South Africa) for
3 min via an anaesthetic gas chamber (100 mg/kg). All
experiments and protocols used in this study were reviewed
and approved by the animal ethics committee of the Uni-
versity of KwaZulu Natal (UKZN) with ethical clearance
numbers 079/14/Animal and 013/15/Animal issued.
Plasmodium parasite
Chloroquine-susceptible strain of Plasmodium berghei
ANKA, murine malaria parasite was a kind donation from
Professor Peter Smith (University of Cape Town, Division
of Clinical Pharmacology, South Africa). The parasite was
sub-cultured, harvested and stored in a Bio Ultra freezer
(Snijers Scientific, Tilburg, Netherlands) at −80 °C until
use.
Experimental design
The study was conducted over 21 day in animal groups
(n = 6 per group) as follows:
Non-infected treated control groups (NIC)
Infected non-treated control groups (IC)
Infected treated with CHQ 30 mg/kg groups (30CHQ)
Infected administered AA 5 mg/kg groups (5 mg)
Infected administered AA 10 mg/kg groups (10 mg)
Infected administered AA 20 mg/kg groups (20 mg)
Methods
Induction of parasitaemia
Chloroquine-susceptible strain of P. berghei ANKA (106
parasitized red blood cells [pRBC’s] suspension in saline)
was inoculated intraperitoneal (ip). Control animals
received equivalent amount of saline. Day of inoculation
was regarded as experiment day 1.
Oral Asiatic acid and chloroquine preparation
Asiatic acid was dissolved in DMSO (0.5 mL) and made up
to volume with distilled water such that the final concen-
tration was 5 mg/kg AA. Dosage was administered as mul-
tiples of the stock volume equivalent to the dose required.
Chloroquine [CHQ] (30 mg/kg) was dissolved in distilled
water. Both compounds were prepared fresh each day.
Monitoring of %parasitaemia
Appearance of parasites in the blood after ip inoculation
takes 2–3 days [28]. Pre-patent period of 72 h post infec-
tion and a stable state parasitaemia at 15–20 % on day 7
without intervention confirmed the models conform to
the known murine malaria course. These periods can be
used as set points for establishing predictive validity of
the experiments. %Parasitaemia was assessed and mea-
sured on day 3 and 7 in infected groups. Treatment was
only commenced when the %parasitaemia had reached
patent level or stable state SM.
Influence of Asiatic acid on biophysical changes
In animals individually housed in metabolic cages, intake
of food, water and body weights of non-treated infected
(IC), non- infected treated (NIC) and infected treated
were monitored gravimetrically at 09 h00 every third day
for experiment duration. The effects of AA on the mea-
sured parameters were compared to those of controls.
Malaria treatment
Rats were treated per oral (po) using a ball-tipped,
18-gauge gavage needle (Kyron Laboratories (Pty) LTD,
Benrose, South Africa) attached to a 1 ml syringe. Due to
preliminary studies on AA posology and literature reports
AA (5, 10, 20 mg/kg) [29] was administered on day 7–12
(5 days), once daily at 09 h00. CHQ (30 mg/kg) was
administered twice daily (09 h00 and 16 h00) according to
local laboratory developed posology [25, 26]. The CHQ
dose of 30 mg/kg was selected although it was larger than
the highest dose of AA (20 mg/kg) because it is treatment
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dose lethal to P. berghei which is closest to AA doses in
the study that has been used by other researchers [30].
Influence of AA administration on % parasitaemia
Peripheral (tail) blood smears were used to monitor
%parasitaemia. The actual number of pRBC’s relative
to 2 × 104 RBC’s was used to calculate parasitaemia [28]. A
15–20 % parasitaemia, confirmed by Giemsa staining under
a microscope (Olympus Cooperation, Tokyo, Japan), was
considered as stable state of severe malaria (SM). For post-
infection AA or CHQ po administration % parasitaemia
was monitored at 72 h (pre-patent period), every third day
up to Day 7 [patent period] [31], every day during treat-
ment period (5 days) and thereafter every other day post-
treatment period until day 21.
Influence of AA administration on malaria anaemia
Changes in full blood count (FBC) were used to further
confirm the influence of AA in reversing low blood
volume experienced in malaria. Animals were sacrificed
on days 0, 8, 12, 21 and blood was collected by cardiac
puncture into EDTA tubes for full blood count analysis.
Statistical analysis
Unless otherwise stated, data was presented as mean ±
standard error of the mean (SEM). Statistical compari-
sons were performed by one way analysis of variance
(ANOVA), followed by Tukey-Kramer multiple compa-
rison post hoc test using GraphPad InStat Software
(version 5, GraphPad Software, San Diego, California USA).
A p < 0.05 considered statistically significant.
Results
Asiatic acid influence in malaria
Per-oral AA administration on %parasitaemia
Figure 1 shows %parasitaemia changes over time. AA
(5, 10, 20 mg/kg) decreased %parasitaemia in comparison
to IC (*p < 0.05) during treatment. AA (5, 10, 20 mg/kg)
administration varied significantly vs 30CHQ on days
8–12 (#p < 0.05). AA (10 mg/kg) decreased %parasitaemia
significantly in comparison to 30CHQ (#p < 0.05) post
treatment period day 15. Peak parasitaemia had signifi-
cantly different time points when AA (5, 10, 20 mg/kg)
administered groups were compared to 30CHQ (#p < 0.05)
over the 21 day study.
AA effects on %parasitaemia-time area under the curves
%parasitaemia-time course, indicated by area under the
curve (AUC), compared the cumulative effect of different
AA doses on the parasite and malaria pathophysiology
to those of IC (AUC0-12days) and CHQ (AUC0-21days) as
shown in Fig. 2. Suppression efficiency and malaria
pathology amelioration of different doses of AA (AA5,
10, 20 mg/kg UC0-21days) was in the order of 10 mg/kg >
5 mg/kg > 20 mg/kg. AA 10 mg/kg administration
lowered the AUC0-21days significantly compared to the IC
AUC0-12days and 30CHQ treatment AUC0-21days (*, # p <
0.05, respectively). AA 20 mg/kg administration had an in-
creased AUC0-21days compared to both the IC AUC0-12days
and 30CHQ AUC0-21days (*, # p < 0.05, respectively).
There was no significant difference in %parasitaemia-time
course of AA5 (AUC0-21days) when compared to CHQ
(AUC0-21days) and IC (AUC0-21days).
Influence of AA on parasitaemia progression compared to
controls
Table 1 showed %parasitaemia-time lines which revealed
that AA doses influence varied according to the different
doses when compared to controls. At day 7 AA20 had
significantly lower %parasitaemia compared to CHQ
Fig. 1 Influence of oral AA on % parasitaemia compared to controls.
IC is infected-non treated control. 30CHQ is chloroquine 30 mg/kg.
Values are presented as means ± SEM, (n= 6 in each group). *, #
p< 0.05 compared to IC, CHQ controls, respectively
Fig. 2 Influence of AA administration on haemoglobin changes over
time. NIC is non infected treated control; IC is infected non treated
control; 30CHQ is chloroquine treated with 30 mg/kg. Values are
presented as means ± SEM, (n = 6 in each group). α,*, # p < 0.05
compared to NIC, IC, CHQ controls
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(* p < 0.05) while other doses did not show significant
differences to controls. At day 7 AA10 displayed a higher
%parasitaemia compared to IC and CHQ (*, #p < 0.05,
respectively). At peak % parasitaemia AA10 administration
had a higher parasitaemia suppression effect compared to
controls (*, #p <0.05.) AA5 and 20 had equally significant
%parasitaemia suppression capacity at peak parasitaemia
compared to CHQ (#p < 0.05). %parasitaemia progression
was faster in AA10 administered animals. From day 3 to
day 7 while it was slowest in AA20 administered animals.
Influence of Asiatic acid on eating and drinking habits as
well as weight changes
Influence of AA on biophysical properties
Food and water intake plus weight changes reflected the
general animal health among AA treated infected animals
compared to controls. Tables 2, 3 and 4 showed the effects
of AA on food and water intake, and %weight change. At
day 12 and 21 food intake of AA administered animals
increased in order of 5 mg/kg > 20 mg/kg > 10 mg/kg vs
IC and 30CHQ (*p < 0.05 and #p < 0.05, respectively).
Administration of 5 and 20 mg/kg AA significantly (*p <
0.05) increased food intake by comparison to the IC on
day 7–12 of treatment. AA administration (5, 10, 20 mg/
kg) significantly increased water intake when compared to
IC and 30CHQ group (*p < 0.05 and #p < 0.05, respect-
ively) at patent/treatment and post treatment time points.
Animals administered AA (5, 10, 20 mg/kg) had increased
%weight change in comparison to IC and 30CHQ (*, #p <
0.05, respectively) during treatment and post treatment
periods. Overall the 10 mg/kg AA had the highest positive
effect on biophysical changes by comparison to all con-
trols (*, #p < 0.05). Generally, AA administration had a
positive influence on the biophysical characteristics of the
experimental animals compared to controls.
Influence of AA on anaemia development and resolution
Influence of AA administration on haemoglobin
Hb concentration estimated the degree of anaemia de-
velopment and resolution compared to controls. Figure 3
AA (10 mg/kg) vs NIC, day 7–12 (α p < 0.05). AA
(10 mg/kg) vs IC on days 7–12 (* p < 0.05). AA (10 mg/
kg) vs 30CHQ on day 7–12 and post treatment (#
p0.05). AA (5 mg/kg) vs NIC on days 7–12 (α p < 0.05).
AA (5 mg/kg) vs IC on days 7–12 (* p < 0.05). AA
(20 mg/kg) vs NIC on days 7–12 and post treatment (α
p < 0.05). AA (20 mg/kg) vs IC on days 7–12 (* p < 0.05).
AA (20 mg/kg) vs 30CHQ on days 7–12 and post treat-
ment (# p < 0.05).
Influence of AA administration on haematocrit compared to
controls
Haematocrit change over time was used as a surrogate
marker for severe malaria anaemia development and
resolution. Compared to the IC, AA10 administration
Table 1 Asiatic acid influence on parasitaemia % time lines compared to controls
Protocol Dose Infection rate Pre-patent (days) % parasitaemia day 3 % parasitaemia range on Day 7 % peak parasitaemia
Post-Infection per
oral treatment
IC 100 % 2–3 3.70 ± 0.675 15.7 ± 3.264 69.3 ± 3.88
30CHQ 100 % 2–3 1.167 ± 0.307 16.1 ± 1.325 43.3 ± 1.66
5AA 100 % 2–3 1.928 ± 0.778 16.9 ± 2.774 41.7 ± 4.51*
10AA 100 % 2–3 3.230 ± 2.209 21.3 ± 3.608*# 27.7 ± 1.96*#
20AA 100 % 2–3 1.815 ± 1.016 8.4 ± 3.848*# 46.2 ± 2.94*
IC infected-non treated control, 30CHQ is chloroquine 30 mg/kg. Values are presented as means ± SEM. (n = 6 in each group)
Table 2 Post-infection AA5, 10, 20 oral administration influence











NIC 12.3 ± 2.3 13 ± 9.0 13.4 ± 1.6
IC 11.5 ± 1.9 6.7 ± 1.3 N/A
30CHQ 12.3 ± 1.8 7.8 ± 2.0 8.6 ± 1.7
5 AA 12.9 ± 1.3 9.8 ± 1.3*# 9.7 ± 1.5*#
10 AA 12.3 ± 1.8 12.9 ± 2*# 13.2 ± 0.72#
20 AA 12.7 ± 1.6 9.2 ± 1.6α* 10.3 ± 1.2#
NIC is non-infected treated control, IC is infected non-treated control and CHQ
is chloroquine control (30 mg/kg). Values are presented as means ± SEM,
(n = 6 in each group). α,*,#p < 0.05 by comparison with NIC, IC, 30CHQ groups,
respectively. NIC non infected treated control, IC infected control,
CHQ chloroquine, AA asiatic acid
Table 3 Post-infection AA5, 10, 20 oral administration influence











NIC 14.3 ± 1.0 15.5 ± 1.3 15.2 ± 0.9
IC 15.5 ± 1.3 8.4 ± 1.7 N/A
CHQ 14.2 ± 1.2 10.5 ± 1.7 12 ± 1.2
5AA 15 ± 3 12.7 ± 1*# 14.8 ± 1.9#
10AA 15.8 ± 0.8 14.2 ± 0.9*# 15.1 ± 1.1#
20AA 15.2 ± 1 11.6 ± 1.7α* 12.9 ± 1.6
NIC is non-infected treated control, IC is infected non-treated control and
CHQ is chloroquine control (30 mg/kg). Values are presented as means ± SEM,
(n = 6 in each group). α,*,#p < 0.05 by comparison with NIC, IC, 30CHQ groups,
respectively. NIC non infected treated control, IC infected control,
CHQ chloroquine, AA asiatic acid
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was shown to influence a higher haematocrit at patent/
treatment periods (*p < 0.05). AA5, 10, 20 administration
had generally lower haematocrit during patent/treatment
and post treatment periods compared to NIC (α p <
0.05). AA10 administration influenced higher haemato-
crit compared to CHQ (# p < 0.05). AA10 administration
proved to be the most efficacious of the three doses
against malaria anaemia development.
Influence of AA administration on red blood cell mass
compared of controls
Red blood cell mass was used as a critical indicator of
anaemia development and resolution Compared to the
IC, AA10 administration was shown to influence a
higher red cell count at patent/ treatment periods (* p <
0.05). AA10 administration influenced higher red cell
count compared to CHQ (# p < 0.05). Compared to NIC
patent/treatment and post treatment period AA admin-
istration had lower red cell count. AA10 administration
proved to be the most potent of the three doses in pro-
tecting red cell count.
Discussion
There is paucity of information with regard to AA treat-
ment of malaria although anti-malaria anecdotal evidence
has been forwarded for Centella asiatica [CA] from which
AA is obtained. P. berghei has a similar pathophysiology
with the P. falciparum, the most virulent human malaria
parasite warranting its use as a murine malaria model.
Studies in our laboratory have indicated, also proven in
earlier research [32], that P. berghei causes severe malaria
(SM) in younger animals which may proceed to cerebral
malaria (CM).
The P. berghei-SD rat malaria model conformed to a
high predictive validity at days 3 and 7 (Table 2) as
expected. Infection effectuation by an ip inoculation of
106 parasitized red blood cells (pRBC’s) saline suspension
invariably resulted in SM. There was no significant
difference in %parasitaemia observed amongst the groups
during the pre-patent and patent periods. Decrease in
%parasitaemia and changes in haematological parameters,
therefore, could be attributable to the intervention.
We used young, 6 weeks old SD rats (90–120 g) which
displayed SM, severe malaria anaemia (SMA) and in some
cerebral malaria (CM) to demonstrate AA influence on
murine malaria, SMA development and its resolution.
Stable state SM was determined as 15–20 % parasitaemia
at day 7 and >20 % at day 12 (Fig. 1) and SMA as an Hb
<7.0 g/dL, Hct <15 % and red cell count <4 × 106/μL
(Figs. 2, 3, 4).
In untreated animals peak parasitaemia was able to
reach 69.3 % (Table 2) and Hb was 4.5 g/dL (Fig. 2) by day
12 when the animals were sacrificed to avert further pain
and suffering. Suppression of parasitaemia to undetectable
levels and resolution of haematological parameters to
normal by administration of AA10mg/kg by day 21
was demonstrated. Once daily administration of AA10
corrected malaria manifestations compared to the IC
and 30CHQ (twice daily treatment).
Partially pharmacodynamics of AA in influencing mal-
aria was shown by comparing the efficacy of the different
AA doses during the 21 day studies. Normally, a drug at
higher concentrations is expected to exert a higher and
more profound an effect and to be less effective at lower
concentrations. While we did not determine the minimum
inhibitory concentration for AA in this study, at highest
(AA20) and lowest (AA5) doses, AA po administration
may have been permissive to parasite growth through
currently unknown mechanisms by displaying higher peak
%parasitaemia comparable to CHQ although significantly
Table 4 Post-infection AA5, 10, 20 oral administration influence












NIC 8 ± 1 14.4 ± 6 18.9 ± 6
IC 10.1 ± 5 4 ± 22.3 N/A
CHQ 8.8 ± 1.5 9.4 ± 6 12.2 ± 0.5
5AA 9.3 ± 2.2 14.2 ± 1.0*# 15.5 ± 1.9#
10AA 8 ± 1 13.7 ± 1* 17.3 ± 0.8#
20AA 9.5 ± 1 11.5 ± 1.9* 13.1 ± 0.2
NIC is non-infected treated control, IC is infected non-treated control and
CHQ is chloroquine control (30 mg/kg). Values are presented as means ± SEM,
(n = 6 in each group). *, #p < 0.05 by comparison with IC and 30CHQ groups,
respectively. NIC non infected treated control, IC infected control, CHQ
chloroquine, AA asiatic acid
Fig. 3 Influence of AA administration on haematocrit changes over
time. NIC is non infected treated control; IC is infected non treated
control; 30CHQ is chloroquine treated with 30 mg/kg. Values are
presented as means ± SEM, (n = 6 in each group). α,*, #p < 0.05
compared to NIC, IC, CHQ controls
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lower than the IC (Table 2). AA5, AA20 and 30CHQ
permitted %parasitaemia to increase by 1.47, 4.5 and 1.69
times, respectively, from day 7 to peak %parasitaemia at
day 21 compared to AA10 which increased by 0.3. It may
be poignant to note that AA20 had the highest effect on
parasitaemia suppression during early days of AA admi-
nistration, thereafter %parasitaemia dramatically increased
subsequently culminating in the highest %parasitaemia-
time course (Figs. 1, 5 and Table 2). Administration of AA5
may not have reached an optimum drug concentration to
be lethal to the parasite during the treatment period while
the AA20 dose may have been too high becoming protec-
tive to the parasite’s survival over time. Administration of
AA10 provided the optimum dose as the suppression of
%parasitaemia was evidenced by a higher patent/treatment
period %parasitaemia without dramatic increase towards
peak %parasitaemia.
The %parasitaemia-time under the curve (AUC) dis-
played the cumulative effect of the different AA doses
collated over 21 days for AA, CHQ and over 12 days for
the IC. Although the %parasitaemia-time course for IC
(IC AUC0-12days) was shorten to 12 days, compared to
21 days for the treated animals, still the latter had a com-
paratively higher AUC showing that AA intervention
resulted in lowering of AA10 AUC0-21days as observed. In-
deed, AA10 administration resulted in a lower AUC0-21days
showing a more potent parasitic suppression effect of AA
at this dose.
The observed continual %parasitaemia decline beyond
AA administration at day 12 implies possible residual
activity of AA with three possible effects: an accumu-
lative AA concentration with increased direct parasite
metabolism disruption or increased malarial pathophy-
siology resolution hostile to parasite survival or immune
system activation. A combination of these and other
phenomena is possible as well. However, this dynamic
milieu, which may be explainable through recognition of
the molecular characteristics of AA, was only attained
by AA10 administration.
The phytochemical AA possesses both antioxidant
(hydrogen bond acceptor 4.172) and pro-oxidant (hydrogen
bond donor 7.1) capacities [11] which may concurrently
function under physiological conditions and may eventually
increase during subsequent dosing with possible chemo-
prophylaxis and chemotherapeutic effects. Hypothetically,
the ratio of the oxidant and antioxidant capacity may
dictate which facet of AA predominates. To the parasite,
an oxidative interaction with AA will be detrimental to its
survival while an antioxidant may be beneficial. There is a
possibility that the optimum redox equilibrium of AA
with a parasite killing potential was obtainable only at
AA10 dose while it was diminished at AA20 and AA5
doses with resultant parasite proliferation seen by day 12.
In malaria, inflammatory response is usually exagge-
rated. The host’s innate immune response to contain para-
sitaemia invariably involves the production and release of
Th1 and Th2 cytokines, chemokines, growth factors,
inflammatory effectors and mediators which throw the
regulatory process off balance resulting in anaemia and
other malaria pathology. AA has anti-inflammatory acti-
vity which could have resolved this pathophysiology,
weakening malaria virulence and suppressing parasitaemia
when AA10 was administered. Furthermore, the immuno-
modulatory effect of AA10 may also have curtailed aber-
rant immune reactivity that is common in malaria by
selectively suppressing activated lymphocytes [21] and
macrophages proliferation with possible enhancement
Fig. 4 Influence of AA administration on red blood cell count
compared to controls. NIC is non infected treated control; IC is
infected non treated control; 30CHQ is chloroquine treated with
30 mg/kg. Values are presented as means ± SEM, (n = 6 in each
group). α,*, #p < 0.05 compared to NIC, IC, CHQ controls
Fig. 5 AUC0-21Days of %parasitaemia for post-infection AA oral ad-
ministration. IC is infected-non treated control. 30CHQ is chloroquine
30 mg/kg. Values are presented as means ± SEM, (n = 6 in each
group). *, # p < 0.05 compared to IC, CHQ controls, respectively
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erythroid lineage propagation. An intricate balance in the
host’s eradication of the parasite exists during malaria pro-
liferation through the production of inducible tumour ne-
crosis factor (TNF), oxygen free radicals and other
inflammatory mediators [33]. This could have implied that
the anti-inflammatory and immunomodulatory effects of
AA20 could have prolonged parasitaemia through over
enhancement of these characteristics.
These the parasite suppression effects or lack off may
also have been facilitated by a dose dependent AA ab-
sorptivity in the small intestines such that higher plasma
concentrations were achieved through higher AA dose
administration. Indeed, AA has been predicated to have a
good intestinal absorption, mild Caco-2 cell permeability
and a strong plasma protein binding [34] and low excre-
tion. The strong protein binding of AA may have caused
possible cumulative concentrations of the compound in
plasma reaching a certain threshold that overwhelmed
parasite defences with rapid parasitaemia decline. More-
over, a high affinity for proteins and low excretion rate
may mean sustained, slow and constant release allowing
AA to reach targets at optimum concentrations influ-
enced by protein plasma concentrations which may be
dependent on food and water intake.
Together with increased suppression of parasitaemia,
administration of AA10 dose was associated with im-
proved food and water intake and preserved weight gain
compared to both 30CHQ dose and IC (Table 1). By
preserving food and water intake at previous levels prior
to infection, AA10 administration rebuffed onset of the
sickness behaviour associated with malaria infection see-
ing that a significantly higher %parasitaemia was reported
at day 7 (Table 2) showing infection patency. Malaria
treatment with current drugs like CHQ does not counter
parasite induced satiate but might actually exacerbate it.
The decreased food and water intake and subsequently
low weight gain in animals treated with CHQ could have
been due a combined effect of both the parasite and the
drug.
Chloroquine, like quinine, is known to have bitter taste
which has been shown to reduce appetite [35]. The
intestinal lining has receptors for both sweet and bitter
substances with the latter associated with influencing
decreased food intake through the gut-brain axis [36].
Nausea and vomiting are some side effects of CHQ which
may increase aversion to food and water intake with wor-
sening malarial pathophysiology, depletion of energy stores
and decreasing foraging capacity. In this study, AA10
administration maintained food and water intake possibly
due to its being tasteless and its antimalarial activity.
Furthermore, the hypoglycaemic effects of AA have
been reported in streptozotocin-induced diabetes melli-
tus where the phytochemical increased activities of
glycolytic enzymes while inhibiting gluconeogenesis and
glycogenolysis [37]. Such an influence occurring in a
normoglyaemic situation may invariably upregulate the en-
ergy mobilization processes to keep pace with the increased
glucose utilization and demand of malaria. With food and
water available ad libitum, an increased appetite as induced
by AA10, physiologically inclines the animals to increase
food and water intake. Therefore, it is plausible to assume
that in malaria, a disease that influences induction of
hypoglycaemia, AA10 had a causal relationship with weight
gain and malaria complications alleviation.
One of the malaria sequalae that was observed to be
averted is severe malaria anaemia (SMA). In malaria,
SMA has multifaceted aetiologies ranging from parasi-
tized red blood cells (pRBC’s) rapture, pRBC’s and non-
parasitized red blood cells (npRBC’s) phagocytosis [31],
insufficient erythropoiesis, ineffective haematopoiesis and
reduced erythropoietin production. While the haema-
tological indices of haemoglobin (Hb) concentration, red
blood cell count (RBC’s) and haematocrit (Hct) were de-
pressed with increasing %parasitaemia in the IC and CHQ
controls, AA10 administration preserved these parameters
and ameliorated SMA. SMA has been shown to persist
even when parasitaemia has been resolved driven by an
aberrant immune system and hemozoin-induced oxidative
stress [38]. Therefore, current finding of AA10 parasi-
taemia suppression may not have been the only effect
retarding and correcting SMA. There is possibility that
more factors (including inflammatory mediators- impaired
erythropoiesis) influencing SMA development may have
been inhibited by AA10 per se together with preserved
food and water intake.
Destruction of pRBC’s occurs when the shyzoints mature
and merozoites rapture cell membranes. Accompanying
pRBC’s destruction is the lysis of npRBC’s at a ratio of 8.5
RBC’s for each pRBC’s haemolysed [39]. Anaemia develops
as the RBC mass is reduced rapidly without concurrent re-
placement. Endogenous secretion of erythropoietin (EPO)
may be overwhelmed by the high demand for erythro-
poiesis stimulation that is required to meet the rapid deve-
lopment of anaemia during the patent period. However, it
was also observed that increasing EPO was not able to alle-
viate SMA associated with high parasitaemia showing that
erythroid precursor response may also be inhibited by
blood stage parasites resulting in low reticulocytosis [40].
Erythroid progenitor suppression in malaria has been
ascribed to the increased free haemoglobin and hemozoin
containing monocytes in the bone marrow and a shift of
the transferrin receptor expression from erythroid to non-
erythroid cell to increase immunological response to
blood-stage parasite [41].
Alleviation of SMA involves the generation of reticulo-
cytes, a process which requires the proliferation, diffe-
rentiation and maturation of erythrocyte precursors in
the bone marrow and other haematopoietic tissues. The
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maintenance of RBC’s count in this study may have
implied that there was sufficient reticulocytosis or there
was minimum RBC’s destruction in AA10 administered
animals compared to controls. However, the decrease in
Hb and Hct at patent in IC and CHQ groups shows
RBC’s destruction as one of the key initiators of SMA
which was minimized by AA10 administration.
The mechanism by which npRBC’s are destroyed in
malaria involves increased erythrocytic oxidative stress
and parasite antigens which cause RBC’s membrane to
be less deformable and more fragile with shortened
RBC’s life spans. These cells are trapped during splenic
sequestration and destroyed through phagocytosis. AA
has known antioxidant, anti-inflammatory and immuno-
modulatory properties which could have protected cell
membranes from oxidative damage and rigidity, reduced
erythrophagocytosis and inhibited parasite proliferation.
Masilinic acid (MA) a phytochemical similar in structure
and polypharmacology with AA was shown to have
multi-targeted inhibitory properties against malaria with
possible blockade of parasite maturation from early ring
to schizont stages [42]. Betulinic and ursolic acids also
share carbon skeleton with MA and AA. Analogues of
these two triterpenes have been shown to be antiplasmo-
dial through disruption of parasite calcium homeostasis
[43]. There is a possibility that AA may also possess the
same inhibitory properties which could have limited
RBC’s haemolysis and preserved haematological indices.
Fully functional murine haemoglobinised RBC’s take
7 days to be formed from an erythroid progenitor.
Haematological indices in AA10 administered animals
reflected the same time span for their recovery to near
pre-infection levels showing an effectuation of a multi-
factorial remedy to SMA by AA10. The pleiotropic
biological effect of AA may have influenced host con-
trol of the parasite through modulation of the immune
system erythropoiesis suppressive effect resulting in
the haematological indices correction towards normal
in AA10 administered animals compared to controls.
The involvement of cytokines and inflammation medi-
ators, such as haeme-parasite derived hemozoin, influ-
ence the differentiation and maturation of erythroid
cells. Increased levels of tumour necrosis factor (TNF),
interleukin 6 (IL6), interleukin 1β (IL1β) and decreased
levels of interleukin 12 have been associated with
SMA [44]. The persistence of SMA beyond parasit-
aemia eradication is orchestrated and sustained by an
immunological sequalae which upregulates hepcidin
synthesis and modulation of iron metabolism [45].
Therefore, resolution of SMA (normalised haemato-
logical indices) indirectly indicated the abrogation of
the immunological and inflammatory processes by
AA10, which properties the triterpene is known to
possess. However, the exact mechanism by which AA10
modulated SMA development and resolution requires
further exploration.
Conclusion
Data demonstrating that AA positively influences food
and water intake, %weight gain, % parasitaemia and SMA
in P. berghei-infected SD rats has been presented. AA may
have both anti-parasitic and anti-disease activities sup-
pressing the parasite while ameliorating infection-induced
pathology. AA10 administration showed a superior effi-
cacy in preservation of food and water intake, parasit-
aemia suppression as well as resolution of SMA.
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